Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 9 for:    severe preeclampsia AND eclampsia | Panama
Previous Study | Return to List | Next Study

Aggressive Versus Expectant Management of Severe Preeclampsia Remote From Term (MEXPRE-Latin)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01164852
Recruitment Status : Completed
First Posted : July 19, 2010
Last Update Posted : August 14, 2012
Sponsor:
Information provided by (Responsible Party):
Paulino Vigil-De Gracia, Complejo Hospitalario Dr. Arnulfo Arias Madrid

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

How best to manage preeclampsia remote from term is controversial because of conflicting maternal and neonatal risks. Gestational age is the most important determinant of neonatal outcome. There are two basic approaches when delivery is not clear indicated by assessment of maternal and fetal well-being. The interventionist care when the delivery is planned within 48 hours and the expectant care which refers to pregnancy prolongation during which time women and fetuses are carefully monitored for indications for delivery.

The purpose of this study is to evaluate maternal and perinatal outcomes with expectant vs interventionist or aggressive management of severe preeclampsia at 28 to 33 weeks of gestation.


Condition or disease Intervention/treatment Phase
Preeclampsia Procedure: Delivery Not Applicable

Detailed Description:
Severa Preeclampsia between 28 and 33 weeks of gestation Women and fetus with stable condition All women receive complete dosis of steroids
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 264 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Expectant Management of Severe Preeclampsia at 28 to 33 Week's Gestation:a Randomized Controlled Trial
Study Start Date : August 2010
Actual Primary Completion Date : August 2012
Actual Study Completion Date : August 2012

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
No Intervention: Expectant management
Expectant management: refers to pregnancy prolongation during which time women and fetuses are carefully monitored for indications for delivery.
Active Comparator: Interventionist management
Interventionist management: in which blood pressure is stabilized, corticosteroids are given for acceleration of fetal maturity and delivery is planned within 48-72 hours.
 Procedure: Delivery
Termination of pregnancy (delivery)after completed corticosteroids
Other Names:
  • Severe preeclampsia
  • expectant management of severe preeclampsia


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Perinatal death [ Time Frame: After begining the randomization until 4 weeks after delivery. ]
    Number of perinatal in each group (interventionist or expectant management)


Secondary Outcome Measures :
  1. Perinatal complications and maternal complications [ Time Frame: Maternal and perinatal complication after begining the randomization until 4 weeks after delivery. ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Pregnancy with severe preeclampsia and 28 to 33 weeks of gestation

Exclusion Criteria:

  • Uncontrollable blood pressure or persistent severe hypertension (160/110 mmHg)
  • Persistent symptoms of preeclampsia
  • Maternal complications (HELLP syndrome, acute renal insufficiency, cerebral edema, eclampsia, pulmonary edema)
  • Fetal death, restriction of fetal grown
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01164852


Locations
Layout table for location information
Ecuador
Hospital Terodoro Maldonado, del IESS
Gauyas, Ecuador
Hospital Carlos Andrade Marin
Quito, Ecuador
Guatemala
Hospital de Gineco-Obstetricia del seguro social
Ciudad Guatemala, Guatemala
Mexico
Hospital de Ginecologia del Instituto Materno Infantil
Toluca, Mexico
Panama
Complejo Hospitalario Caja de Seguro Social
Panamá, Panama
Hospital Santo Tomás
Panamá, Panama
Peru
Hospital Nacional Madre Niño, Lima Perú
Lima, Peru
Venezuela
Hospital Nuestra Señora de Chiquinquira
Maracaibo, Venezuela
Sponsors and Collaborators
Complejo Hospitalario Dr. Arnulfo Arias Madrid
Investigators
Layout table for investigator information
Principal Investigator: Paulino Vigil-De Gracia, MD Complejo Hospitalario
Study Chair: Jack Ludmir, MD Pennsylvania Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Paulino Vigil-De Gracia, Paulino Emilio Vigil De Gracia, Complejo Hospitalario Dr. Arnulfo Arias Madrid
ClinicalTrials.gov Identifier: NCT01164852    
Other Study ID Numbers: ComplejoH 01
First Posted: July 19, 2010    Key Record Dates
Last Update Posted: August 14, 2012
Last Verified: August 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Pre-Eclampsia
Hypertension, Pregnancy-Induced
Pregnancy Complications